INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune syndrome that primarily affects women of childbearing age. Although life expectancy in SLE has improved, estimated mortality rates remain approximately three times that of the general population [1] . Importantly, although deaths due to lupus manifestations have decreased, those because of atherosclerotic cardiovascular disease (CVD) in SLE have not. Indeed, CVD accounts for more than one-third of all deaths in SLE patients [2, 3] . Outcomes of percutaneous coronary intervention are worse in SLE patients than in matched controls, with regard to the need for repeat vascularization and major adverse cardiac events [4] . Overall, SLE patients have higher incidence of CVD present with this complication earlier than agematched and gender-matched controls [5] , and have an accelerated rate of plaque progression [6] . The risk for myocardial infarction (MI) in SLE patients is 9-50-fold that of the general population, depending on the series [7] . Although the Framingham risk equation [8] contributes to vascular risk in SLE, it cannot fully explain it [9, 10] . Indeed, although the absolute risk for CVD increases with age, the highest increment in relative risk for acute MI occurs in young females with SLE [11] . Furthermore, atherosclerosis in SLE is atypical not only because it affects premenopausal women but because it is not associated with the 'classical' inflammatory burden characteristic of 'idiopathic' atherosclerosis, such as elevated C-reactive protein (CRP) and elevated levels of plasma low-density lipoprotein (LDL).
In SLE, disease duration, higher damage index score and less aggressive immunosuppression are associated with increased CVD burden [12,13 state of lupus, and evidence suggests that similar factors may be implicated in development and progression of CVD [15 & ]. Furthermore, murine models suggest a synergism between genes that promote atherogenesis with those that promote autoimmunity, although the relationship between enhanced plaque and more profound systemic immune dysregulation requires further elucidation [16 & ].
ENDOTHELIAL DYSFUNCTION AND ABERRANT METABOLIC PATHWAYS IN SYSTEMIC LUPUS ERYTHEMATOSUS
SLE patients demonstrate endothelial dysfunction, a phenomenon considered to correlate with poor cardiovascular outcomes in other populations. A very significant proportion of SLE patients display impaired endothelium-dependent vasorelaxation [17] and enhanced arterial stiffness [18] . The subset of patients affected by lupus nephritis appears to be at a particularly increased risk for arterial stiffness [19] . Cardiac positron-emission tomography (PET) has revealed impaired microvascular blood flow and reduced coronary flow reserve in SLE patients [20 && ]. Atherosclerosis occurs in the arterial subendothelial space and is initiated by the interplay between subendothelial lipoprotein retention and endothelial dysfunction that leads to a nonresolving inflammatory response that generates endothelial damage and atherothrombosis [21] . Although many atherosclerotic lesions undergo a partial fibrotic protective resolution [22] , some individuals develop 'vulnerable plaques' that are more prone to breakdown and subsequent development of acute coronary syndrome. These vulnerable areas are characterized by intimal necrosis, enhanced inflammation, and fibrous cap thinning. It has been proposed that plaque necrosis results from a combination of defective clearance of apoptotic cells, and primary necrosis of these cells, quite similar to defects on the immune system observed in other organs from lupus patients [23] [24] [25] . However, whether this represents a common mechanism that explains enhanced atherogenesis in SLE and whether lupus patients have increased prevalence of vulnerable plaque remains to be determined [26] .
Thirty-five percent of adult SLE patients [27] and 60% of pediatric SLE patients have abnormal lipoprotein profiles at diagnosis [28] , and prevalence increases to 60% of adults in a 3-year follow up in the Systemic Lupus International Collaborating Clinics cohort [27] . In SLE, a described pattern of dyslipidemia is characterized by increased very lowdensity lipoprotein (VLDL) and triglycerides, and decreased high-density lipoprotein (HDL) [29] . This pattern is often seen at time of diagnosis and correlates to SLE activity [30] . Oxidized LDL/b2-glycoprotein 1 immune complexes have also been described [31] , which bind oxidized LDL (oxLDL) and are phagocytosed by macrophages promoting foam cell formation.
Along with the effects of LDL, SLE HDL is dysfunctional and proatherogenic. Indeed, a main antiatherogenic property of HDL is the cholesterol efflux capacity, and this is impaired in SLE with no association to plasma level of the lipoprotein [32] . This proinflammatory nature of lupus HDL appears to be driven by enhanced oxidative modifications triggered, at least in part, by neutrophil extracellular traps (NETs) [33] . Apolipoprotein levels and ratios are also disturbed in SLE, possibly due to anti-apolipoprotein antibodies [34] . However, outside of enhanced HDL oxidation and dysfunction, none of the dyslipidemias or apolipoproteins has been found to predict subclinical atherosclerosis or cardioprotection in SLE [35] .
Several studies [36] [37] [38] [39] ] and there is evidence for increases in macrophage proinflammatory subsets M1 and M2b, and decreases in the antiinflammatory M2a and M2c populations in SLE, which may contribute to inflammation [64] . IFNs drive macrophages to engulf lipids [48] , and enhanced monocyte migration to plaque site increases foam cell production. FcRyIIB is an inhibitory member of the family of Fc receptors (FcR). FcRyIIB knockout mice were found to have lower lipid levels yet had larger atherosclerotic plaques [15 & ]. Lack of FcRyIIB promotes both autoantibody production in SLE and promotes atherosclerosis in mice [65, 66] .
Adaptive immunity B cells and autoantibodies
Subpopulations of B cells may alter risk for cardiovascular events, as B1 cells have been described as protective in CVD, whereas B2 cells appear to be pathogenic. B1 cells produce natural antibodies to oxidized LDLs, thus conferring potential cardioprotection ( Fig. 1) [67] . Patients with SLE have decreased levels of protective immunoglobulin M (IgM) antibodies against the apolipoprotein B (apoB)-100 antigens p45 and p210, and these are further reduced in SLE patients with CVD [68] . Recently, a dysfunctional feedback loop between regulatory B cells and plasmacytoid dendritic cells (pDCs) has been implicated in the pathogenesis of SLE [69 & ]. Interestingly, B cell depletion restores normal regulatory feedback in SLE and also reduces atherosclerosis [70] .
Immune complexes are identified in atherosclerotic plaques, but evidence remains conflicting over whether they drive plaque formation or vascular damage. Recent evidence suggests that they may amplify endothelial damage through cytolysis and interruption of phagocytosis and autophagy, causing inflammation and increase in plaque ]. These prothrombotic factors may add to SLE cardiovascular risk. [33] , while Treg cells are decreased in number and function; this may contribute to autoimmunity and inflammation [75] . Tregs may protect against atherosclerosis, as they improve endothelial function, inhibit B cell activation, and the production of inflammatory cytokines. Proatherogenic ApoEÀ/À mice have a significantly lower number of Tregs compared with wild type [76] , and Treg deficient mice show increased atherosclerotic lesions and plaque vulnerability [77] . Whether this Treg imbalance is implicated in atherogenesis in SLE remains to be determined.
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Screening
Risk factors
As traditional risk factors contribute to cardiovascular risk in SLE, it is imperative that smoking cessation, healthy weight, and exercise are encouraged. Recently published adult guidelines recommend the following: initial risk assessment of lipid profile, blood pressure and fasting glucose assessment, tobacco exposure, and plasma homocysteine evaluation; high-sensitivity C-reactive protein and SLE monitoring labs at each visit, and yearly assessment of aPL antibodies [78 && ]. Carotid intima media thickness (CIMT) monitoring is recommended for patients with less than one risk factor or renal disease but their utility needs to be further validated. In childhood-onset SLE, no imaging has yet proven robust for surrogate of atherosclerosis and screening guidelines remain to be developed [13 & ]. It is unclear if these modifications will mitigate cardiovascular risk in subsets of SLE patients. Other noninvasive markers of reversible endothelial dysfunction, such as flow-mediated vasodilation (FMD) and reactive hyperemia-peripheral arterial tonometry (RH-PAT) have been reported to be increased in SLE patients, but require further validation in large studies [79, 80] .
Biomarkers are needed to serve as reliable surrogates for atherosclerotic disease in SLE. Novel methods able to determine which SLE patients are at increased risk for CVD are also of interest. Recently, the PREDICTS model that uses a combination of inflammatory and metabolic markers (inflammatory HDL, leptin, TWEAK, homocysteine, age, and diabetes status) demonstrated good predictive capacity for development of atherosclerosis in female SLE patients in short-term follow up [81] . As neutrophils may play important roles involved in both SLE and atherosclerosis pathogenesis, the proteins S100A8, A9, A8/9, and A12 (secreted by activated neutrophils and associated to inflammation and atherosclerosis) [82 && ] have been proposed as putative biomarkers but remain to be validated. Indeed, in the general population, elevation of these proteins predicts future cardiovascular events [83] , and use of these alarmins as CVD biomarkers warrants investigation in SLE. Carotid ultrasound and computed tomography (CT) for coronary calcification assessment have been used to predict subclinical atherosclerosis in SLE in research studies, but may only identify a small subset of individuals with damage and at risk for cardiovascular events. It is not only the quantity of plaque, but its quality, that needs to be further examined in these individuals. Assessments of vascular inflammation, unstable plaque, and microvascular disease should be studied for risk stratification in SLE. 18 
Therapeutic targets
Statins
Statins are a cornerstone of treatment in atherosclerosis through pleiotropic metabolic and anti-inflammatory effects [88] [89] [90] . Previous studies on the use of statins in SLE have been overall small in size and not shown improvement in outcomes, despite improved lipoprotein profiles [91] . More recently, specific statins were shown to modulate distinct inflammatory pathways [92] . Simvastatin lowers small LDL-IgG-immune complex levels more effectively than levels of LDL-cholesterol and LDL-apoB levels in individuals with atherosclerosis vasculoprotective effects [95] . Hydroxychloroquine has been shown to inhibit IFN production by pDCs, which may account for the reduced risk [96] . In murine models of SLE, hydroxychloroquine decreased reactive oxygen species production via nicotinamide adenine dinucleotide phosphate, improving nitric oxide availability and preventing endothelial dysfunction [97 && ]. Antimalarials also inhibit NET formation in vitro and this could have a putative vasculoprotective role [98] .
Insulin resistance
Insulin resistance in SLE is associated with traditional cardiovascular risk factors as well as higher levels of oxLDL and end organ damage [41, 99] . Therapy aimed at improving insulin resistance therefore holds promise for ameliorating some of the excess cardiovascular risk of SLE. Metformin downregulates NET formation and IFN generation, and was shown to decrease SLE flares in a recent pilot study [100] . However, whether metformin will be efficacious is reducing cardiovascular risk in SLE requires further investigation. Peroxisome proliferator-activated receptor-g (PPAR-g) is a transcription factor involved in lipid metabolism, inflammation, insulin resistance, and vascular health by inhibiting leukocyte and endothelial cell interaction in endothelial cells [101
&&
]. PPAR-g-treated mice showed significant decreases in immune complex deposition, renal inflammation, improvement in insulin resistance, adipokine, and lipid profile, and reduced SLE associated atherosclerosis [102] [103] [104] , making this an interesting prospect of therapy for CVD in SLE [105] . Indeed, a recent pilot study performed in patients with rheumatoid arthritis who received the PPAR agonist pioglitazone indicated a significant modulatory effect on vascular function and inflammation, suggesting that this class of drugs could be investigated in SLE.
Vitamin D Vitamin D deficiency is common in patients with SLE, and has been associated with CVD in the general population [106] . SLE patients with low vitamin D are at higher risk for cardiovascular events [107, 108] , and have increased aortic stiffness [109, 107] . Treatment with vitamin D improved myeloid angiogenic cell numbers and function, possibly through downregulation of interferon gamma-inducible protein 10 [110 && ] and regulation of nitric oxide in endothelial cells [111] . A small study [112] suggests vitamin D repletion may benefit endothelial function in SLE, but large prospective studies are needed to determine the role of vitamin D supplementation in cardioprotection for SLE.
Biologics
Other anti-inflammatory therapies, such as anti-IL6 [113] and TNF inhibitors [114] are currently in clinical trials to decrease cardiovascular risk in patients with rheumatoid arthritis. In SLE, targeting B cells through anti-B Lymphocyte stimulator [67] or anti-CD20 [67] may have the potential to reduce endothelial dysfunction but this remains to be further investigated. Given recent positive results with antitype I IFN receptor trials for SLE disease activity [115] and the putative role that these cytokines play in atherogenesis in SLE, it will be important to determine their role in cardiovascular health in this disease.
CONCLUSION
Cardiovascular disease is not only an important comorbidity of SLE, but similar proinflammatory and dysregulated immune pathways may lead to shared pathogenesis of these two conditions. Prospective studies are needed to determine ideal monitoring for subclinical disease (Table 1) , prevention of atherosclerosis, and aggressive treatment of ongoing CVD to reduce the excessive risk for SLE patients.
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